Should We Add Avastin (Bevacizumab) to Tarceva (Erlotinib) for EGFR Mutation-Positive NSCLC?


I recently had the honor of providing the expert commentary at the ASCO 2014 conference on three high impact lung cancer presentations, all on the subject of treatment options for molecularly defined populations (EGFR and ALK). I'll review the findings from these three abstracts and my perspective on each of these, starting with a very provocative presentation by Dr.

Subscribe to L858R substitution